Gujarat Terce Laboratories (BOM:524314) Cyclically Adjusted Revenue per Share: ₹63.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524314 Gujarat Terce Laboratories Ltd BOM:524314
41 GF Score
Price ₹37.62
! 2 Warning Signs
View Full Analysis

What is Gujarat Terce Laboratories Cyclically Adjusted Revenue per Share?

Gujarat Terce Laboratories BOM:524314 +3.49% 41 Cyclically Adjusted Revenue per Share is ₹63.00 as of Jun. 2026. GuruFocus rates BOM:524314 with a GF Score™ of 41/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Gujarat Terce Laboratories's adjusted revenue per share for the three months ended in Jun. 2026 was ₹11.627. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹63.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Gujarat Terce Laboratories's average Cyclically Adjusted Revenue Growth Rate was 5.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -3.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Gujarat Terce Laboratories was 4.70% per year. The lowest was -8.50% per year. And the median was -2.80% per year.

As of today (2026-08-22), Gujarat Terce Laboratories's current stock price is ₹37.62. Gujarat Terce Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹63.00. Gujarat Terce Laboratories's Cyclically Adjusted PS Ratio of today is 0.60.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Gujarat Terce Laboratories was 1.57. The lowest was 0.09. And the median was 0.54.


Gujarat Terce Laboratories  (BOM:524314) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Gujarat Terce Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=37.62/63.00
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Gujarat Terce Laboratories was 1.57. The lowest was 0.09. And the median was 0.54.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Gujarat Terce Laboratories Cyclically Adjusted Revenue per Share Related Terms


Gujarat Terce Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Gujarat Terce Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gujarat Terce Laboratories Cyclically Adjusted Revenue per Share Chart

Gujarat Terce Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.71 53.86 56.27 58.48 61.77

Gujarat Terce Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.62 60.93 61.40 61.77 63.00

BOM:524314 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Terce Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gujarat Terce Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gujarat Terce Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Gujarat Terce Laboratories's Cyclically Adjusted PS Ratio falls into.


BOM:524314
41GF Score
Gujarat Terce Laboratories Ltd BOM:524314
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gujarat Terce Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gujarat Terce Laboratories's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=11.627/167.3573*167.3573
=11.627

Current CPI (Jun. 2026) = 167.3573.

Gujarat Terce Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 11.580 105.961 18.290
201612 8.234 105.196 13.100
201703 7.270 105.196 11.566
201706 5.975 107.109 9.336
201709 11.002 109.021 16.889
201712 10.364 109.404 15.854
201803 11.680 109.786 17.805
201806 9.083 111.317 13.656
201809 10.733 115.142 15.600
201812 11.261 115.142 16.368
201903 9.746 118.202 13.799
201906 9.349 120.880 12.944
201909 15.024 123.175 20.413
201912 13.720 126.235 18.189
202003 12.592 124.705 16.899
202006 6.712 127.000 8.845
202009 9.701 130.118 12.477
202012 9.471 130.889 12.110
202103 7.863 131.771 9.987
202106 13.412 134.084 16.740
202109 13.621 135.847 16.780
202112 14.414 138.161 17.460
202203 12.579 138.822 15.165
202206 12.697 142.347 14.928
202209 16.867 144.661 19.513
202212 16.044 145.763 18.421
202303 17.298 146.865 19.712
202306 14.426 150.280 16.065
202309 16.174 151.492 17.868
202312 17.612 152.924 19.274
202403 16.999 153.035 18.590
202406 15.321 155.789 16.459
202409 17.948 157.882 19.025
202412 16.228 158.323 17.154
202503 16.607 157.552 17.641
202506 14.970 159.755 15.682
202509 16.576 162.289 17.094
202512 15.344 163.281 15.727
202603 14.673 164.272 14.949
202606 11.627 167.357 11.627

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹63.00 mean?
Gujarat Terce Laboratories (BOM:524314) has a Cyclically Adjusted Revenue per Share of ₹63.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Gujarat Terce Laboratories and its competitors.
Is Gujarat Terce Laboratories' Cyclically Adjusted Revenue per Share too high?
Gujarat Terce Laboratories' current Cyclically Adjusted Revenue per Share is ₹63.00. Overall, Gujarat Terce Laboratories has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Gujarat Terce Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS?
Gujarat Terce Laboratories' Cyclically Adjusted Revenue per Share of ₹63.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Gujarat Terce Laboratories and its competitors. Gujarat Terce Laboratories's current Cyclically Adjusted Revenue per Share is ₹63.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Terce Laboratories stock overvalued right now?
Gujarat Terce Laboratories (BOM:524314) has a current Cyclically Adjusted Revenue per Share of ₹63.00. The current Cyclically Adjusted Revenue per Share is ₹63.00. Gujarat Terce Laboratories' overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Gujarat Terce Laboratories (BOM:524314), the current Cyclically Adjusted Revenue per Share is ₹63.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gujarat Terce Laboratories Business Description

Address Near Shivalik High-Street, Unit No. D/801-802 and 1202,The First, Behind Keshavbaug Party Plot, Vastrapur, Ahmedabad, GJ, IND, 380015
Gujarat Terce Laboratories Ltd is an Indian company having business in the medical and pharmaceutical preparations. It is engaged in the manufacturing of tablets, capsules, syrup, and injections. It offers branded as well as generic formulations covering different therapeutic areas such as antibiotics, respiratory, nutraceuticals, gastrointestinal, antifungal, and many more. Some of the main brands are Acolate, Tynol, DFS, Resplash, Aziter, and others.
41GF Score

Get the complete analysis for BOM:524314

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹37.62
Price